Podcast appearances and mentions of robert wilonsky

Robert Wilonsky's 16th Annual Christmas Spectacular December 24th, 2024 Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

July 11th, 2024 While all the other shows are talking about Hard Knocks & Receiver on Netflix, Robert Wilonsky & David Moore review the one that actually means the most. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket's Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

Robert takes you backstage of the historic Longhorn Ballroom for the Macho Self Storage Jub Jam 2024 with multiple Ticket hosts & intimate performances, presented by Maestro Dobell Tequila, and the official beer of Jub Jam, Zigenbock. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket's Website And follow The Ticket Top 10 on Apple, Spotify or Amazon Music See omnystudio.com/listener for privacy information.

February 14th, 2024 For the last Intentional Grounding of the 2023-2024 Football season, we cap it off with Fox 4's Mike Doocy & Sam Gannon joining Robert Wilonsky & David Moore in studio to discuss the addition of Mike Zimmer as defensive coordinator. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket's Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

Join best friends and ex-roommates Robert Wilonsky & David Moore as they breakdown the Cowboys & their win against Detroit & getting ready for Washington in their season finale Sunday. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket's Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

December 25th, 2023 - Robert Wilonsky's 15th Annual Christmas SpectacularSee omnystudio.com/listener for privacy information.

Join best friends and ex-roommates Robert Wilonsky & David Moore as they breakdown the Cowboys getting ready to head to Buffalo and reflecting on beating Philly. Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket's Website And follow The Ticket Top 10 on Apple, Spotify or Amazon Music See omnystudio.com/listener for privacy information.

THIS VOYAGE, MARK A. ALTMAN (author, The Fifty Year Mission, showrunner, Pandora, writer/producer Agent X, The Librarians, writer/producer Free Enterprise), DAREN DOCHTERMAN (associate producer, Star Trek: The Motion Picture - Director's Edition, concept designer: Master & Commander, Westworld) and ASHLEY E. MILLER (showrunner; DOTA: Dragon's Blood, writer, X-Men: First Class, Thor) are joined by ROBERT WILONSKY (VP of Marketing and Publicity for Heritage Auctions) to talk about the incredible auction of The Greg Jein Collection taking place October 14 - 15th. This is a once-in-a-lifetime auction of the most magnificent #StarTrek collection ever assembled along with invaluable artifacts from BATMAN, BUCK ROGERS, BATTLESTAR GALACTICA, STAR WARS and more. Don't miss this special episode and an opportunity to get a archival catalog from the auction.   SUBSCRIBE TODAY TO TREKSPERTS PLUS... and get every episode of INGLORIOUS TREKSPERTS and our new podcast, INGLORIOUS TREKSPERTS presents DECK 78 along with additional bonus content and surprises all season long. For more details, visit trekkspertsplus.com.  Join Mark A. Altman (Pandora, The Librarians) and Ashley E. Miller (Thor, X-Men: First Class, DOTA: Dragon's Fire) at NIGHTMARE WEEKEND in Richmond, VA this October. Visit galaxycon.com for details. Learn all that is learnable about Star Trek in Mark A. Altman & Edward Gross' THE FIFTY-YEAR MISSION, available in hardcover, paperback, digital and audio from St. Maritn's Press. And if you're a James Bond fan, don't miss NOBODY DOES IT BETTER, in hardcover, paperback, digital and audio from Forge Books. And don't miss SECRETS OF THE FORCE, the definitive unauthorized, uncensored oral history of STAR WARS, now available in hardcover, digital and audio!!  Follow Inglorious Treksperts at @inglorioustrek on Twitter, Facebook, Blue Sky and at @inglorioustreksperts on Instagram and Threads. And now follow the Treksperts Briefing Room at @trekspertsBR, an entirely separate Twitter & Instagram feed. Email us at trekspertsplus@gmail.com "Mark A. Altman is the world's foremost Trekspert" - Los Angeles Times #StarTrek #TOS #TAS #TNG #DS9 #VOY #ENT #DISCO #PICARD #LLAP #comics #IDW #Marvel #DC #GoldKey #Discovery #DeepSpaceNine #STTMP #StarWars  #CaptainPike #StrangeNewWorlds #55YearTour  #casting #ST55 #StarTrek55 #TheCage #StrangeNewWorlds #SNW #Voyager #Janeway #Enterprise #TheSearchForSpock #StarTrekIII #BSG #TMP #Trekkies #Alien #Aliens #DavidFincher #BestofTrek #EnterpriseIncidents #IDW #comics #DS9 #DeepSpaceNine #TerryFarrell #NanaVisitor #PicardSeason3 #StarTrekPicard #Picard #Borg #PicardSeason3 #StarTrekPicard #M5 #TrueFoodKitchen #Andor #PIcardSeason3 #trekspertsplus.com #GregJein #HeritageAuctions

6.14.23.See omny.fm/listener for privacy information.

After three months of trying to do something that resembled a podcast, The Continuing Adventures of Crizzle and Camilo is coming to a close with this episode. Hell, Camilo doesn't even appear in this one. (He had a job interview.) This leaves Crizzle all by his lonesome to talk to veteran Dallas journalist Robert Wilonsky. They talk about that crazy time Crizzle met him in Dallas, Wilonsky's career as a journalist, how superhero movies are becoming tiresome (even to a comic-book nerd like Wilonsky), the current state of pop-culture journalism, and Wilonsky's current gig at auction house Heritage Auctions. This is such a bittersweet episode, Crizzle forgot to ask dude if he washes his ass. You can holla at Craig at @unclecrizzle. You can holla at Camilo at @camilohannibal.

3.29.23.See omnystudio.com/listener for privacy information.

Robert Wilonsky and David Moore filling in for a vacationing Norm & D talk to one of Robert's old colleagues, writer and film critic Matt Zoller Seitz. 7.8.22 See omnystudio.com/listener for privacy information.

Robert Wilonsky and David Moore take a spin around The Star and tell us what we need to look for as the Cowboys prepare for the up-coming training camp. 7.8.22 See omnystudio.com/listener for privacy information.

Robert Wilonsky and David Moore dive into the Dallas Cowboys offseason and how life is going at The Star. 6.24.22 See omnystudio.com/listener for privacy information.

11-16-2021 See omnystudio.com/listener for privacy information.

10-20-2021 See omnystudio.com/listener for privacy information.

Former city reporter Robert Wilonsky joins the show talking about his new gig with Heritage Auctions and how telling good stories will always be a the core of what he does and what he enjoys.

Former city reporter Robert Wilonsky joins the show talking about his new gig with Heritage Auctions and how telling good stories will always be a the core of what he does and what he enjoys.

Former city reporter Robert Wilonsky joins the show talking about his new gig with Heritage Auctions and how telling good stories will always be a the core of what he does and what he enjoys.

Former city reporter Robert Wilonsky joins the show talking about his new gig with Heritage Auctions and how telling good stories will always be a the core of what he does and what he enjoys.

1-21-2021 See omnystudio.com/listener for privacy information.

Mike sits down with Dallas journalism legend Robert Wilonsky regarding his change in career path, influential figures in their careers, the Times Herland, The Zoo, what the city of Dallas means to them and more on Square One.   Get 40% off at The Athletic with link theathletic.com/rhyner Learn more about your ad choices. Visit megaphone.fm/adchoices

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

In this episode, Dallas native Robert Wilonsky, Director of Communications for Heritage Auctions and Op-ed Columnist for the Dallas Morning News, joins the podcast to provide perspective on the city he loves during the COVID-19 pandemic. Wilonsky shares the same Northwest Dallas neighborhood as host Paul Corliss, and they discuss what makes their little corner of the city a special community that helps them maintain a sense of normalcy during social distancing and stay-at-home ordinances.

On this Fridays Dump we have some extra crap from Robert Wilonsky and David Moore's Oscar show and BaD Radio have a super fake but real sports discussion.

This week, Travel Today with Peter Greenberg comes from the Statler Dallas in Dallas, Texas. Larry Horwitz, Executive Director of the Historic Hotels of America explains the significance of Statler Dallas in the travel industry as well as the importance of the hotels across the country in the historic hotels portfolio. In addition, curator for the Dallas Historical Society, Alan Olsen, highlights its “Dallas in the Time of MLK” exhibit, which focuses on the time Dr. Martin Luther King Jr. spent in Dallas. Then, Vice President of Community & School Engagement of the Perot Museum, Teresa Lenling, discusses the stand-out exhibits at the museum and how they cover a multitude of interests, from paleontology to space. Robert Wilonsky, a columnist at the Dallas Morning News stops by to discuss the importance of journalism in the city and his experience as a seasoned columnist. Kerry Adams, Collections & Exhibits Director at the Old Red Museum of Dallas County History & Culture stops by to explain that there's much more to Dallas than tourists from out of town expect. Lastly, Michael VanHuss, Director of Development & Operations at The Statler Dallas explains the importance of the hotel to the city and how the hotel has continued to evolve as a historical landmark in Dallas. There’s all of this and more as Travel Today with Peter Greenberg comes from the Statler Dallas in Dallas, Texas.

This week, Travel Today with Peter Greenberg comes from the Statler Dallas in Dallas, Texas. Larry Horwitz, Executive Director of the Historic Hotels of America explains the significance of Statler Dallas in the travel industry as well as the importance of the hotels across the country in the historic hotels portfolio. In addition, curator for the Dallas Historical Society, Alan Olsen, highlights its “Dallas in the Time of MLK” exhibit, which focuses on the time Dr. Martin Luther King Jr. spent in Dallas. Then, Vice President of Community & School Engagement of the Perot Museum, Teresa Lenling, discusses the stand-out exhibits at the museum and how they cover a multitude of interests, from paleontology to space. Robert Wilonsky, a columnist at the Dallas Morning News stops by to discuss the importance of journalism in the city and his experience as a seasoned columnist. Kerry Adams, Collections & Exhibits Director at the Old Red Museum of Dallas County History & Culture stops by to explain that there's much more to Dallas than tourists from out of town expect. Lastly, Michael VanHuss, Director of Development & Operations at The Statler Dallas explains the importance of the hotel to the city and how the hotel has continued to evolve as a historical landmark in Dallas. There’s all of this and more as Travel Today with Peter Greenberg comes from the Statler Dallas in Dallas, Texas.

Dallas Morning News City Columnist Robert Wilonsky discusses a wide range of topics with TC Fleming.

The legendary funnyman from SportsRadio 1310 The Ticket shares his deep thoughts on Tony Romo, Skip Bayless, drinking, not drinking, the war between bears and humans, Robert Wilonsky's sonorous voice, his own lack of ambition, and the high school girlfriend that he can never forget, among other topics.

In honor of Bill Paxton, we look at his star turn/directorial debut Frailty, as well as the crime spree that loosely inspired it. Frailty (2001) “The Day Bill Paxton Saw John F. Kennedy” by Robert Wilonsky, from The Dallas Observer “Joseph Kallinger: The Shoemaker” by Christopher Greenlief, Amanda Hall, and Jenna Hafey, from Radford University Department […] The post Episode 16: Frailty (For Bill) appeared first on TEST PATTERN with Jacob and Tab.

Robert Wilonsky!